Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Dose Study of JNJ-75220795 in Japanese Participants with Fatty Liver
jRCT2071210066Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing JNJ-75220795 75 mg SC single dose with Placebo SC single dose (2 arms). Primary endpoints: Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events, Number of Participants With Change From Baseline in Vital Signs Abnormalities and 3 more. Started May 2022; status: completed.
02
Drugs
ARO-PNPLA3
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on jRCT2071210066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210066.